Jain Akash, Marimuthu Varun, Alur Nagamani
Department of Cardiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru, India.
IHJ Cardiovasc Case Rep. 2022 Oct-Dec;6(4):169-171. doi: 10.1016/j.ihjccr.2022.09.008. Epub 2022 Oct 7.
The ChAdOx1 nCoV-19 adenoviral vector-based vaccine was the first to be approved against COVID-19 in India. Vaccine induced thrombotic thrombocytopenia (VITT) is a rare but serious adverse effect of the ChAdOx1 nCoV-19 vaccine, causing widespread thrombosis and thrombocytopenia. A 22-year-old patient, who had undergone mechanical mitral valve replacement, presented to us one week after administration of 1st dose of the ChAdOx1 nCoV-19 Coronavirus vaccine with acute prosthetic heart valve thrombosis (PVT). Laboratory investigations revealed thrombocytopenia and high D-Dimer levels, suggestive of probable VITT. In this report, we highlight the importance of identification of VITT as a cause of PVT and discuss management options.
基于ChAdOx1 nCoV-19腺病毒载体的疫苗是印度首个获批用于对抗新冠病毒病的疫苗。疫苗诱导的血栓性血小板减少症（VITT）是ChAdOx1 nCoV-19疫苗一种罕见但严重的不良反应，可导致广泛的血栓形成和血小板减少。一名22岁接受机械二尖瓣置换术的患者，在接种第一剂ChAdOx1 nCoV-19冠状病毒疫苗一周后，出现急性人工心脏瓣膜血栓形成（PVT）并前来就诊。实验室检查显示血小板减少和D-二聚体水平升高，提示可能为VITT。在本报告中，我们强调了识别VITT作为PVT病因的重要性，并讨论了管理方案。
